Meta-analysis suggests about 8,500 daily steps may help limit weight regain after dieting

Проверено фактами

An international meta-analysis slated for presentation at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (May 12–15) suggests that people who increase their walking to roughly 8,500 steps a day during a weight-loss program and sustain similar levels afterward may be less likely to regain weight.

A systematic review and meta-analysis led by Professor Marwan El Ghoch of the University of Modena and Reggio Emilia assessed randomized controlled trials examining step-count-based lifestyle programs and weight outcomes.

Researchers screened 18 trials and included 14 randomized controlled trials comprising 3,758 adults in the final meta-analysis. Across the trials, participants in lifestyle modification programs combined dietary guidance with recommendations to walk more and track daily steps.

By the end of the weight-loss phase (average duration 7.9 months), people in the lifestyle modification programs increased their walking to an average of 8,454 steps per day and lost an average of 4.39% of their body weight (about 4 kg, as reported in the conference materials).

By the end of the maintenance phase (average duration 10.3 months), participants were still averaging 8,241 steps per day and, on average, maintained most of their loss, with an average long-term weight loss of 3.28% (about 3 kg).

The analysis also reported that higher step counts were associated with less weight regain over time, while increased walking was not linked to greater weight loss during the initial dieting period. The researchers described increasing walking to around 8,500 steps per day as a practical strategy to support weight-loss maintenance.

Связанные статьи

An overweight adult on a couch with a Fitbit showing low activity and GLP-1 medication nearby, illustrating study findings on reduced physical activity.
Изображение, созданное ИИ

Study: Physical activity fell after some patients with obesity started GLP-1 drugs

Сообщено ИИ Изображение, созданное ИИ Проверено фактами

Adults with obesity who began taking GLP-1 receptor agonist medications showed declines in Fitbit-measured physical activity after starting treatment, according to a retrospective study presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.

Just a few minutes of activity that leaves people out of breath each day was associated with substantially lower risks of developing eight major diseases and of dying over about seven years in a study of roughly 96,000 UK Biobank participants who wore wrist accelerometers for a week. The research, published March 30, 2026 in the European Heart Journal, suggests that how intensely people move may matter alongside how much they move.

Сообщено ИИ Проверено фактами

A small 2023 study of adults with obesity in China found that an intermittent energy restriction program was associated with weight loss and changes in gut bacteria alongside altered activity in brain regions linked to appetite, cravings and self-control.

A new analysis of clinical trials indicates that semaglutide, the active ingredient in Ozempic and Wegovy, helps older adults with obesity lose substantial weight and improve heart health markers. The findings come from data on participants aged 65 and above who received the once-weekly medication alongside lifestyle changes.

Сообщено ИИ

A Yale University study has found that nearly half of adults age 65 and older showed measurable improvements in cognitive function, physical function, or both over a period of up to 12 years. The research draws on data from more than 11,000 participants and links positive age beliefs to these gains. It challenges the view that aging always involves decline.

Этот сайт использует куки

Мы используем куки для анализа, чтобы улучшить наш сайт. Прочитайте нашу политику конфиденциальности для дополнительной информации.
Отклонить